Table 3.

Responder analysis. Proportion of participants with at least 30, 50, 75, or 100% reduction in pain severity

	Treatment groups		Group differences
% pain reduction	ET	SMT+ET	SMT+ET minus ET (95% CI)
Week 12 *
No reduction or increase	21.6%	14.1%	−7.5 (−18.7 to 3.8)
≥ 30%	61.4%	60.9%	−0.5 (−1.44 to 1.35)
≥ 50%	46.6%	47.8%	1.2 (−0.16 to 0.13)
≥ 75%	13.6%	29.4%	15.7 (3.7 to 27.2)
100%	5.7%	15.2%	9.5 (0.4 to 18.8)
Week 26 ^
No reduction or increase	21.2%	8.9%	−12.3 (−23.0 to −1.7)
≥ 30%	63.5%	77.8%	14.2 (0.8 to 27.2)
≥ 50%	42.4%	67.8%	25.4 (10.7 to 38.7)
≥ 75%	17.7%	38.9%	21.2 (7.9 to 33.5)
100%	5.9%	20.0%	14.1 (4.1 to 24.1)
Week 52 †
No reduction or increase	25.6%	10.0%	−15.6 (−26.7 to −4.3)
≥ 30%	65.1%	77.8%	12.7 (−0.7 to 25.5)
≥ 50%	51.2%	62.2%	11.1 (−3.5 to 25.0)
≥ 75%	27.9%	33.3%	5.4 (−8.1 to 18.7)
100%	12.8%	16.7%	3.9 (−6.8 to 14.4)

^*Analysis included 88 participants in ET group and 92 in SMT+ET group

^{^}Analysis included 85 participants in ET group and 90 in SMT+ET group

^†Analysis included 86 participants in ET group and 90 in SMT+ET group